TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25592205

Group type: EXPERIMENTAL
Intervention: Computerized auditory cognitive training (ACT)
Number of subjects: 17
Study: 24469525

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 22559752

Group type: EXPERIMENTAL
Intervention: Docetaxel with doxorubicin and cyclophosphamide (TAC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5-fluorouracil, doxorubicin, cyclophosphamide (FAC)
Number of subjects: 100
Study: 18574553

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil administered on hemodialysis day (HD day group)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Olmesartan medoxomil administered on non-dialysis day (non HD day group)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (both groups)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Blood pressure and heart rate measurements (both groups)
Number of subjects: 6
Study: 17306707

Group type: EXPERIMENTAL
Intervention: Carvedilol therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 25
Study: 15352911

Group type: EXPERIMENTAL
Intervention: High-dose induction interferon-alpha2b (5 million units daily for 4 weeks) followed by standard dose therapy (3 million units three times a week for 44 weeks for genotype 1 or 20 weeks for non-genotype 1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard dose therapy (3 million units three times a week for total treatment duration)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 45
Study: 11235793

Group type: EXPERIMENTAL
Intervention: 28 h of sleep deprivation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Alcohol up to 0.1% BAC
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Circadian rhythm effect
Number of subjects: 39

Group type: COMPARATOR
Intervention: Drivers (compared to controls)
Number of subjects: 39
Study: 10404791

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (HRT)
Number of subjects: 595

Group type: COMPARATOR
Intervention: No hormonal replacement therapy (Control)
Number of subjects: 595
Study: 7550205

Group type: EXPERIMENTAL
Intervention: Postural drainage and manual chest percussion (Treatment A)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Breathing through a commercial device with oscillating positive expiratory pressure (Treatment B)
Number of subjects: 14
Study: 2404590

Group type: EXPERIMENTAL
Intervention: Sputum cytodiagnosis evaluated by trained cytotechnologists
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Observer A
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Observer B
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Within observer discordant readings
Number of subjects: 130
Study: 6987028

Group type: COMPARATOR
Intervention: Metoprolol (single oral doses of 25, 50, 75, 100, or 150 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Metoprolol (multiple doses at 25, 50, or 100 mg thrice daily)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30709668

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical Aortic Valve Replacement (SAVR)
Number of subjects: 0
Study: 27761980

Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri CP2305 administered daily for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri CP2305
Number of subjects: 0
Study: 25833666

Group type: EXPERIMENTAL
Intervention: Pharmacist medication review with face-to-face pharmacist prescribing
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Pharmacist medication review with feedback to general practitioner
Number of subjects: 125

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 125
Study: 24219193

Group type: EXPERIMENTAL
Intervention: Multimodal exercise intervention (1-hour session, three times a week for 16 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no activity during the same period)
Number of subjects: 30
Study: 21054515

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO), dosage and duration not specified
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 19824054

Group type: EXPERIMENTAL
Intervention: SFC (salmeterol 50 microg/FP 100 microg twice daily)
Number of subjects: 283

Group type: COMPARATOR
Intervention: FP (fluticasone proprionate 200 microg twice daily)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: SFC
Number of subjects: 283

Group type: COMPARATOR
Intervention: FP
Number of subjects: 283
Study: 18528511

Group type: EXPERIMENTAL
Intervention: Telemedicine case management (N = 844)
Number of subjects: 1665

Group type: COMPARATOR
Intervention: Usual care (N = 821)
Number of subjects: 1665
Study: 12919181

Group type: EXPERIMENTAL
Intervention: YM337 + ASA + UFH
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: YM337 alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ASA + UFH + YM337
Number of subjects: 18

Group type: COMPARATOR
Intervention: ASA (placebo) + UFH (placebo) + YM337
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ASA + UFH
Number of subjects: 18
Study: 10952772

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (Gem Vin) at dose level I (1000/25 mg/m(2))
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (Gem Vin) at dose level II (1200/25 mg/m(2))
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (Gem Vin) at dose level III (1000/30 mg/m(2))
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (Gem Vin) overall
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (Gem Vin)
Number of subjects: 126
Study: 9002810

Group type: EXPERIMENTAL
Intervention: HEMA‐glutaraldehyde bonding agent
Number of subjects: 40

Group type: COMPARATOR
Intervention: formamide‐containing bonding agent
Number of subjects: 40
Study: 1361274

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure recordings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Office blood pressure measurements
Number of subjects: 0
Study: 6238209

Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate (MPA) therapy
Number of subjects: 27
Study: 3539830

Group type: EXPERIMENTAL
Intervention: Biostim (8 mg daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Biostim (2 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31811333

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (single bolus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (for low cortisol level patients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (for high cortisol level patients)
Number of subjects: 0
Study: 29709490

Group type: EXPERIMENTAL
Intervention: Monomorbid schizophrenia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both psychiatric and substance use comorbidities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comorbid substance use alone
Number of subjects: 0
Study: 26554619

Group type: EXPERIMENTAL
Intervention: 10 mg hyoscine‐N‐butylbromide
Number of subjects: 150
Study: 24874316

Group type: EXPERIMENTAL
Intervention: Cortexin (10 mg three times a day intramuscularly, two courses)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Cortexin (10 mg three times a day intramuscularly, one course)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo (two courses)
Number of subjects: 272
Study: 22509337

Group type: EXPERIMENTAL
Intervention: Valacyclovir (500 mg twice daily)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 148
Study: 20116145

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) pathway
Number of subjects: 452

Group type: COMPARATOR
Intervention: Conventional perioperative care
Number of subjects: 452
Study: 18937844

Group type: EXPERIMENTAL
Intervention: Bar graph (BG group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Bar graph plus frequency format diagram (BG+FF group)
Number of subjects: 150
Study: 15720087

Group type: EXPERIMENTAL
Intervention: 585 nm pulsed-dye laser (single treatment)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 585 nm pulsed-dye laser (double treatment)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (periorbital region without treatment)
Number of subjects: 58
Study: 12882865

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO) therapy, applied twice a day, 5 days a week for 2 weeks, each session lasting 90 min at 2.5 ATA.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO) therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 28
Study: 10959507

Group type: EXPERIMENTAL
Intervention: Long-term treatment protocol (LTP) with 60 microg PGE1, 5 days each week for 4 weeks, followed by twice a week for 4 weeks, then no drugs for 3 months.
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Short-term treatment protocol (STP) with 20 microg on the first day, 40 microg in the afternoon, and 60 microg on the second day, then 60 microg bid for subsequent cycles.
Number of subjects: 980

Group type: COMPARATOR
Intervention: Cost analysis of LTP
Number of subjects: 980

Group type: COMPARATOR
Intervention: Cost analysis of STP
Number of subjects: 980
Study: 8648221

Group type: EXPERIMENTAL
Intervention: 15 microgram of rHA0
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 45 microgram of rHA0
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 135 microgram of rHA0
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subvirion trivalent influenza vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 1465038

Group type: EXPERIMENTAL
Intervention: 25 micrograms oestradiol administered as vaginal pessaries daily for 3 weeks prior to surgery
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo administered as vaginal pessaries daily for 3 weeks prior to surgery
Number of subjects: 48
Study: 6371367

Group type: EXPERIMENTAL
Intervention: Fluorhydrocortisone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 40
Study: 31376560

Group type: EXPERIMENTAL
Intervention: Low-grade heterotopic ossification (HO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-grade heterotopic ossification (HO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No heterotopic ossification (HO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 0
Study: 30411133

Group type: EXPERIMENTAL
Intervention: Ultrasound diamond instrument
Number of subjects: 32

Group type: COMPARATOR
Intervention: High-speed hand piece with regular diamond burs
Number of subjects: 32
Study: 27595110

Group type: EXPERIMENTAL
Intervention: Gel containing 3% ethanolic extract of Brazilian green propolis (EEP-B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gel without EEP-B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gel containing EEP-B
Number of subjects: 0
Study: 24744316

Group type: EXPERIMENTAL
Intervention: 25 g/d RM + 25 g of maltodextrin/d
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 50 g/d RM + 0 g/d maltodextrin
Number of subjects: 14

Group type: COMPARATOR
Intervention: 0 g/d RM + 50 g/d maltodextrin (placebo)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 25 g/d RM
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 50 g/d RM
Number of subjects: 14
Study: 22738882

Group type: EXPERIMENTAL
Intervention: 16-gauge needle
Number of subjects: 250

Group type: COMPARATOR
Intervention: 18-gauge needle
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 250
Study: 20167145

Group type: EXPERIMENTAL
Intervention: BUD/FM pMDI 160/9 micrograms twice daily (320/18 micrograms daily)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: BUD/FM pMDI 320/9 micrograms once daily (evening)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: BUD/FM pMDI 160/9 micrograms once daily (evening)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: BUD pMDI 320 micrograms once daily (evening)
Number of subjects: 752

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 752
Study: 18431588

Group type: EXPERIMENTAL
Intervention: TA-assisted PPV
Number of subjects: 774

Group type: COMPARATOR
Intervention: Conventional PPV
Number of subjects: 774
Study: 16412352

Group type: EXPERIMENTAL
Intervention: Vitamin K(1) group (10 mg per day for 2 to 7 days, antenatal administration)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group (no vitamin K(1) treatment)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Vitamin K(1) group
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 177
Study: 12852709

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% ophthalmic solution
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo eyedrops (artificial tears)
Number of subjects: 131
Study: 10803723

Group type: EXPERIMENTAL
Intervention: Multiple Imputation (MI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methods for handling informative dropouts
Number of subjects: 0
Study: 8645026

Group type: EXPERIMENTAL
Intervention: Anti-emetic administration group
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo administration group
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Total score of 13 descriptive items
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Linear analogue scale
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Face scale
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Physiological scale
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Psychological scale
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Active scale
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Descriptive items
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: QOL measurement
Number of subjects: 98
Study: 1463154

Group type: EXPERIMENTAL
Intervention: i.v. midazolam (17 patients; 2.85 +/- 0.84 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: sublingual flunitrazepam (16 patients; 0.005 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: no sedation (17 patients; controls)
Number of subjects: 50
Study: 2418736

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfacetamide-polymyxin B-neomycin-gramicidin (TSP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimethoprim-polymyxin B (TP)
Number of subjects: 0
Study: 30739305

Group type: EXPERIMENTAL
Intervention: PFT-guided DAPT de-escalation (switch from prasugrel to clopidogrel)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Uniform prasugrel (control group)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (prasugrel)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: De-escalation group (clopidogrel)
Number of subjects: 151
Study: 29632098

Group type: EXPERIMENTAL
Intervention: Preventicus BP smartphone algorithm
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reference device (Omron‐HBP‐1300)
Number of subjects: 32
Study: 27070747

Group type: EXPERIMENTAL
Intervention: 5 % maximal contraction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 % maximal contraction
Number of subjects: 20
Study: 24953293

Group type: EXPERIMENTAL
Intervention: Rush oral immunotherapy (OIT) with peanuts, ingested 3-5 times a day every 30 minutes, increasing the dose by 20% each time, goal dose 3.5-7 g
Number of subjects: 18
Study: 22706327

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg twice daily
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 20148372

Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Albuterol plus caffeine placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Albuterol with 3 mg/kg caffeine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Albuterol with 6 mg/kg caffeine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Albuterol with 9 mg/kg caffeine
Number of subjects: 10
Study: 18356845

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Aerobic Training (AT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: No Training (NT)
Number of subjects: 94
Study: 15988611

Group type: EXPERIMENTAL
Intervention: Polyethylene FRC
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ceramic
Number of subjects: 14

Group type: COMPARATOR
Intervention: Restorative composite
Number of subjects: 14

Group type: COMPARATOR
Intervention: Glass FRC
Number of subjects: 14
Study: 12090979

Group type: COMPARATOR
Intervention: Allogeneic fresh platelets
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Autologous cryopreserved platelets
Number of subjects: 20
Study: 10525070

Group type: EXPERIMENTAL
Intervention: Chlorprothixene administered intravenously
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Chlorprothixene administered orally
Number of subjects: 8
Study: 7551370

Group type: EXPERIMENTAL
Intervention: Y-24180 (20 mg twice a day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2281761

Group type: EXPERIMENTAL
Intervention: Functional cast allowing free range of motion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dorsal/ulnar plaster cast immobilizing the wrist and joints
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Functional cast
Number of subjects: 100
Study: 233160

Group type: EXPERIMENTAL
Intervention: Low dose fluphenazine decanoate (1.25 mg to 5.0 mg biweekly)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 30189768

Group type: EXPERIMENTAL
Intervention: Sutures
Number of subjects: 746

Group type: COMPARATOR
Intervention: Staples
Number of subjects: 746
Study: 31474134

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Tranexamic acid (TXA)
Number of subjects: 235
Study: 29100681

Group type: EXPERIMENTAL
Intervention: Bupivacaine group (n = 11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo group (n = 12)
Number of subjects: 23
Study: 26338891

Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High-Fructose Corn Syrup (HFCS55)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: All sugars (honey, sucrose, HFCS55)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (no sugar intake)
Number of subjects: 55
Study: 23147161

Group type: EXPERIMENTAL
Intervention: Hepcidin-25 levels (measured with mass spectrometry)
Number of subjects: 405
Study: 21606858

Group type: EXPERIMENTAL
Intervention: HR-dependent recovery time (FT80)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (2-minute recovery)
Number of subjects: 21
Study: 18031520

Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg bid
Number of subjects: 4600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4600
Study: 16525572

Group type: EXPERIMENTAL
Intervention: Ximelagatran plus ASA (36 mg and 72 mg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ximelagatran plus ASA (72 mg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus ASA
Number of subjects: 62
Study: 14514744

Group type: EXPERIMENTAL
Intervention: Monthly Qa plus standard surveillance (dynamic venous pressure and physical examination)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard surveillance alone
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Treatment group (monthly Qa plus standard surveillance)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (standard surveillance alone)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) therapy at baseline
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Higher baseline Qa
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Longer interval since graft insertion
Number of subjects: 112
Study: 11068300

Group type: EXPERIMENTAL
Intervention: Functional Magnetic Stimulation (FMS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 32
Study: 9048387

Group type: COMPARATOR
Intervention: General endotracheal anesthesia alone (Group I)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: General endotracheal anesthesia with epidural augmentation (Group II)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia only (Group III)
Number of subjects: 195
Study: 7861794

Group type: EXPERIMENTAL
Intervention: DUI treatment program
Number of subjects: 7316
Study: 2800889

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin (IMP)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Piperacillin plus amikacin (PA)
Number of subjects: 83
Study: 998633

Group type: EXPERIMENTAL
Intervention: Filtered intravenous solutions
Number of subjects: 49

Group type: COMPARATOR
Intervention: Unfiltered intravenous solutions (Control)
Number of subjects: 49
Study: 31999606

Group type: EXPERIMENTAL
Intervention: Essential oil inhaler (AromaStick®)
Number of subjects: 0
Study: 30134143

Group type: EXPERIMENTAL
Intervention: Hand hygiene intervention in kindergartens only
Number of subjects: 8275

Group type: EXPERIMENTAL
Intervention: Hand hygiene intervention in both kindergartens and families
Number of subjects: 8275

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 8275
Study: 28314326

Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 864

Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Second-line therapy (with maintenance)
Number of subjects: 864
Study: 25676422

Group type: EXPERIMENTAL
Intervention: Imatinib (IM)
Number of subjects: 1503

Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg
Number of subjects: 1503

Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg and IM 400 mg plus interferon α (IFN)
Number of subjects: 1503
Study: 24390040

Group type: EXPERIMENTAL
Intervention: Rose odorant application
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo application
Number of subjects: 27